Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omarigliptin Add-on Therapy in Japanese Patients with Type 2 Diabetes
NCT01697592Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2012
- Primary completion
- May 2014
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of omarigliptin in type 2 diabetes mellitus (T2DM) (10 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants Who Experienced at Least One Adverse Event at 52 weeks and Percentage of Participants Who Discontinued From the Study Due to an Adverse Event at 52 weeks. Started Oct 2012; status: completed.
02
Drugs
omarigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01697592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01697592.